Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group maintains a strong liquidity position, with a liquidity_fpt of 0.85, indicating that its cash and equivalents cover a significant portion of its short-term obligations. The company's return on equity (ROE) of 15.71% and return on assets (ROA) of 13.92% are well above the median for the Pharmaceuticals industry, suggesting efficient use of equity and assets to generate profits. The company's profitability is further underscored by its gross profit margin of 89.9%, which is significantly higher than the industry median. This indicates that Hansoh Pharmaceutical Group is able to maintain high margins on its pharmaceutical products, likely due to its strong R&D capabilities and product differentiation in key therapeutic areas. Geographically, Hansoh Pharmaceutical Group is heavily concentrated in the domestic market, with the majority of its revenue derived from operations within China. This concentration may expose the company to regulatory and economic risks specific to the Chinese market, but it also allows for a focused strategy in a large and growing healthcare market. Looking ahead, the company is projected to experience a revenue growth of 12.3% in the current fiscal year and 9.8% in the next fiscal year. This growth trajectory is supported by the continued demand for its innovative drug products, including Ameile, Hansoh Xinfu, and Mailingda, which are used in oncology and other therapeutic areas. The risk assessment for Hansoh Pharmaceutical Group indicates a low probability of dilution and liquidity risk. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no long-term debt obligations. Recent events, including analyst estimates and price targets, indicate a positive outlook for the company. The mean price target of 45.88 CNY and a mean recommendation of 1.70 (on a scale from 1 to 5) suggest that analysts are generally optimistic about the company's future performance.